Reduced ACE2 expression combined with expression of immunomodulators could contribute to lower COVID-19 susceptibility for patients with nonallergic asthma, and this hypothesis is supported by a growing body of preclinical and clinical evidence [29, 32–37]. This evidence concerns the gene ACE2 and asthma.